Key terms
About GLYC
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GLYC news
Mar 01
9:32am ET
GlycoMimetics Provides Update with Investor Presentation
Feb 22
7:46am ET
Promising Outlook for GlycoMimetics’ Uproleselan in AML Treatment: A Buy Rating with Adjusted Price Target
Jan 26
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 05
11:06am ET
GlycoMimetics data reaffirm Sickle Cell opportunity, says Capital One
Jan 04
7:12am ET
GlycoMimetics announces GMI-1687 trial met primary, secondary endpoints
Jan 03
9:26am ET
Buy Rating Affirmed for GlycoMimetics Amidst Phase 3 Progress and Breakthrough Therapy Designation for Uproleselan
Jan 03
7:06am ET
Apollomics completes enrollment in Phase 3 bridging study of APL-106
Jan 02
4:41pm ET
GlycoMimetics in manufacturing pact with Thermo Fisher for uproleselan
Dec 22
6:18am ET
GlycoMimetics initiated with an Overweight at Capital One
Dec 11
6:16am ET
Promising Outlook for GlycoMimetics’ Uproleselan Drives Buy Rating
No recent news articles are available for GLYC
No recent press releases are available for GLYC
GLYC Financials
Key terms
Ad Feedback
GLYC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GLYC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range